Quality of life assessment in pulmonary arterial hypertensio
Not Applicable
Completed
- Conditions
- Quality of lifePulmonary arterial hypertensionCardiovascular - Diseases of the vasculature and circulation including the lymphatic system
- Registration Number
- ACTRN12608000139370
- Lead Sponsor
- Curtin University of Technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Diagnosis of pulmonary arterial hypertension
Exclusion Criteria
Non-English speaking
Major psychological or mood disorders
Cognitive impairment that precludes informed consent and ability to complete questionnaires and follow instructions
Severe musculoskeletal limitations that impair exercise performance
Severe neurological limitations
Co-morbid cardiovascular and/or pulmonary disease
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life questionnaire (CAMPHOR) scores[test, retest (2 weeks)]
- Secondary Outcome Measures
Name Time Method il[Nil]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted in PAH therapies validated by CAMPHOR in Australian/NZ populations?
How does CAMPHOR compare to other QoL tools in evaluating PAH treatment outcomes in ANZ populations?
Which biomarkers correlate with CAMPHOR scores in predicting PAH patient outcomes?
What adverse events impact quality of life in PAH patients using CAMPHOR assessments in ANZ studies?
How does CAMPHOR validation influence the use of phosphodiesterase-5 inhibitors in PAH management in Australia and New Zealand?